News | Fairs | Press Releases
Visit us at various virtual trade fairs
Despite the restrictions caused by the Corona, you can still stay in contact with our Business Development - at virtual trade fairs.
LTS receives notice of allowance for U.S. patent related to Asenapine patch
The United States Patent and Trademark Office has issued the notice of allowance for its U.S. Patent Application entitled "Transdermal Therapeutic System Containing Asenapine“.
LTS signs research collaboration agreement for Micro Array Patches
LTS Lohmann Therapie-Systeme AG has entered into a research collaboration agreement for the evaluation of LTS Micro Array Patch (MAP) technology.
LTS presents Microarray Patches at the Developments and Innovations in the Drug Delivery Market
Dr. Sebastian Braun will present “Dissolvable microarray systems - An industry view regarding development and manufacturing of a new dosage form”.
New web seminar Microarray patch systems
Microneedle systems - is easier to ship, easier to use and painless for the patient. Join this free web seminar to understand the advantages of microneedle systems.
LTS receives the “Highest Reputation” award
The "Highest Reputation" award for LTS. The study assessed the reputation for Management, Sustainability, Products and Services, Performance as Employer, and Business Performance.
LTS marketing campaign, a complete success – awarded!
LTS's very emotional "Animals" marketing campaign has received an extraordinary positive response. The LTS campaign was awarded 2 times.
LTS and LIVZON enter into license and collaboration agreement to develop and commercialize ASENAPINE TTS
LTS AG and Livzon Pharmaceutical Group Inc. announced today that the companies have entered into an exclusive license and collaboration agreement. LTS grants to LIVZON and its Affiliates an exclusive royalty-bearing, sublicensable right and license to jointly develop with LTS the Asenapine TTS and commercialize the Asenapine TTS for the treatment of schizophrenia in China (including Hong Kong and Macau).
New LTS Web seminar
LTS will host a web seminar titled ‘LTS Oral Thin Film Technology – Adaptable like a Chameleon’
LTS appoints Bas van Buijtenen as new Chief Executive Officer
LTS Lohmann Therapie-Systeme AG is very pleased to announce the appointment of Mr. Bas van Buijtenen to the role of Chief Executive Officer effective 1 June 2020.
LTS provides new insights
On 17.02. LTS has installed its first digital information display in Lohmannstraße, directly in front of the LTS gate.
Completion of solar panel installation at LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is pleased to announce the completion of the installation of solar panels atop of its warehouse building of its US affiliate, LTS Lohmann Therapy Systems, Corp.
LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp.
LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.
European patent granted for LTS’ asenapine TTS
An European Patent for LTS’ application relating to an asenapine transdermal therapeutic system (TTS).
Meet us at the CPHI worldwide in Frankfurt
Meet the LTS-Team at CPhI Worldwide 2019 from 5 - 7 November in Frankfurt at our booth 121A70.
German health authorities grant LTS the manufacturer’s authorisation for capsules
Inspection successfully concluded. In September, the German health authorities extended the manufacturer’s authorisation for LTS Lohmann Therapie-Systeme AG (LTS) to include capsules.
The LTS company kindergarten celebrates its 10th birthday
10 year’s anniversary of LTS Wichtelgarten
LTS donates fire-truck to Zichow fire brigade!
The LTS plant fire brigade donates a decommissioned fire-fighting vehicle to the Zichow fire brigade, whose fire-truck has burnt down during a fire in the engine house in February of this year.
Changes in the Supervisory Board of the LTS AG
On June 28th 2019, the shareholders meeting of the LTS AG has elected the four represen¬tatives of the equity owners to the supervisory board of the LTS AG.
LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis.